Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Zohar

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Statistics in Medicine|January 14, 2016
Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'Marie-Karelle Riviere, Sarah Zohar
Statistics in Medicine|June 4, 2015
An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safetySatoshi Teramukai, Takashi Daimon, Sarah Zohar
Statistics in Medicine|February 24, 2011
An approach to meta-analysis of dose-finding studiesSarah Zohar, Sandrine Katsahian, John O'Quigley
Statistics in Medicine|July 19, 2012
A Bayesian predictive sample size selection design for single-arm exploratory clinical trialsSatoshi Teramukai, Takashi Daimon, Sarah Zohar
Clinical Trials (London, England)|August 13, 2011
Incorporating lower grade toxicity information into dose finding designsAlexia Iasonos, Sarah Zohar, John O'Quigley
Pharmaceutical Statistics|November 16, 2018
Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitationPaola Berchialla, Sarah Zohar, Ileana Baldi
Contemporary Clinical Trials|January 19, 2008
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorialSarah Zohar, Satoshi Teramukai, Yinghui Zhou
Statistics in Medicine|December 11, 2014
Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. WagesMarie-Karelle Riviere, Frédéric Dubois, Sarah Zohar
Clinical Trials (London, England)|August 10, 2011
Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case studySarah Zohar, Matthieu Resche-Rigon, Sylvie Chevret
Clinical Trials (London, England)|November 26, 2008
Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomesMatthieu Resche-Rigon, Sarah Zohar, Sylvie Chevret
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Statistics in Medicine|January 14, 2016
Comments on 'A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies'Marie-Karelle Riviere, Sarah Zohar
Statistics in Medicine|June 4, 2015
An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safetySatoshi Teramukai, Takashi Daimon, Sarah Zohar
Statistics in Medicine|February 24, 2011
An approach to meta-analysis of dose-finding studiesSarah Zohar, Sandrine Katsahian, John O'Quigley
Statistics in Medicine|July 19, 2012
A Bayesian predictive sample size selection design for single-arm exploratory clinical trialsSatoshi Teramukai, Takashi Daimon, Sarah Zohar
Clinical Trials (London, England)|August 13, 2011
Incorporating lower grade toxicity information into dose finding designsAlexia Iasonos, Sarah Zohar, John O'Quigley
Pharmaceutical Statistics|November 16, 2018
Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitationPaola Berchialla, Sarah Zohar, Ileana Baldi
Contemporary Clinical Trials|January 19, 2008
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorialSarah Zohar, Satoshi Teramukai, Yinghui Zhou
Statistics in Medicine|December 11, 2014
Response to comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by G. Yin, R. Lin and N. WagesMarie-Karelle Riviere, Frédéric Dubois, Sarah Zohar
Clinical Trials (London, England)|August 10, 2011
Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case studySarah Zohar, Matthieu Resche-Rigon, Sylvie Chevret
Clinical Trials (London, England)|November 26, 2008
Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomesMatthieu Resche-Rigon, Sarah Zohar, Sylvie Chevret
Pageof 9